SDC1 and triple-negative breast carcinoma: CD138, also known as Syndecan-1, has also been recently investigated as a potential target for antibody-conjugated drug therapies for multiple myeloma as well as in a wide variety of cancer types, including bladder cancer and triple-negative breast cancer due to overexpression in these malignancies [25–28].